Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen individualized therapeutic cancer vaccine, TG4050 at SITC 2024 on November 9, 2024 (see ...

Dr. Emmanuelle Dochy, chief medical officer of Transgene, added: "We are very encouraged to observe that all the patients treated with our neoantigen cancer vaccine TG4050 remain disease-free after a ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its ...

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, announces further promising data from the fully enrolled Phase 1b/2 study ...

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

As a key player in protein synthesis, mRNA technology is transforming therapeutics, offering solutions for cancer, genetic disorders, and regenerative medicine.

PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free ...